EGFR inhibition has a large impact on the tumor microenvironment through activation of ADCC via NK cells, promoting cross-talk between NK cells and dendritic presenting cells (DC), and priming cytotoxic T cells [93]. The gene discussed is EGFR; the disease is neoplasm.